Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01107964 · ClinicalTrials.gov registry record · NA

Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome

A NA study of Dry Eye Syndrome, sponsored by Milton S. Hershey Medical Center.

Completed
Registry status
NA
Development phase
27
Enrollment target
1
Study location

NCT01107964 is a NA study of Dry Eye Syndrome that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 27 participants, below the 162-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01107964, a NA study of Dry Eye Syndrome, has completed, sponsored by Milton S. Hershey Medical Center.

COMPLETED
Registry status
NA
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline, Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with lissamine green, and fluorescein tear break-up time) when compared to administration of placebo.

Conditions Studied

Interventions

  • DRUG Oral Omega-3-acid ethyl esters
  • DRUG Placebo corn oil capsule

Study Locations (1)

Pennsylvania

  • Penn State Hershey Eye Center - Hershey

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2010-07
Est. Completion 2015-06-15
Phase NA

Sponsor

Milton S. Hershey Medical Center

396 total trials

What the Registry Record Tells You About NCT01107964

The ClinicalTrials.gov registry entry for NCT01107964 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (83% lower). The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dry Eye Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Oral Omega-3-acid ethyl esters is the first listed.

NCT01107964 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01107964 about?

NCT01107964 is a clinical study titled "Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome". The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline, Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with lissamine green, and fluore...

What is the current status of trial NCT01107964?

This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2010-07. Estimated completion is 2015-06-15.

What conditions does trial NCT01107964 study?

This clinical trial studies the following conditions: Dry Eye Syndrome.

What interventions are being tested in trial NCT01107964?

The interventions under investigation include: Oral Omega-3-acid ethyl esters (DRUG), Placebo corn oil capsule (DRUG).

Who is sponsoring clinical trial NCT01107964?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01107964 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.